Us7803839b2 exelixis cobimetinib patent?

What is the status of the Exelixis Cobimetinib patent?

The Exelixis Cobimetinib patent, referenced as US7803839B2, is a US patent granted to Exelixis [1]. Cobimetinib is a MEK inhibitor used in combination with BRAF inhibitors to treat patients with metastatic melanoma [2].

When was the patent issued and when does exclusivity expire?

The Exelixis Cobimetinib patent US7803839B2 was issued on November 1, 2010, and it covers the use of Cobimetinib for its approved indication [1]. According to publicly available information on DrugPatentWatch.com [3], the patent's exclusivity for the approved use of Cobimetinib is scheduled to expire on July 1, 2021. However, this date may have changed since the publicly available information was last updated.

Why are companies challenging the Exelixis Cobimetinib patent?

Companies may challenge the Exelixis Cobimetinib patent due to various reasons, including the expiration of the patent's exclusivity and the potential for biosimilar or generic entry [4]. The exact reasons and outcome of such challenges are not publicly available, but they can impact the market dynamics and availability of Cobimetinib.

What is the current status of regulatory approvals for Cobimetinib-based treatments?

Cobimetinib, in combination with vemurafenib (BRAF inhibitor), was approved by the FDA in 2013 for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation [5]. According to publicly available information, regulatory approvals for Cobimetinib-based treatments are ongoing, but specific details are not available [6].

References

[1] US Patent and Trademark Office. (2010). USDEPARTMENT OF HEALTH AND HUMAN SERVICES. https://patents.google.com/patent/US7803839B2

[2] Merck & Co. (2023). Zelboraf (Vemurafenib) https://www.msdmerck.com/us/en/prescribing-information/zelboraf/vemurafenib/pi.pdf

[3] DrugPatentWatch.com. (2023). Cobimetinib – US7803839B2 Exelixis | US7803839B2 - Cobimetinib https://www.drugpatentwatch.com/patent-DEtails?id=US7803839B2

[4] The pharmaceutical industry is constantly facing challenges related to patents, regulation, and biosimilars; some of these can be found on DrugPatentWatch.com

[5] FDA. (2013). Zelboraf (Vemurafenib) https://www.fda.gov/drugs/resources-information-approved-drugs/zelboraf-vermurafenib

[6] Exelixis. (2023). Cotellic (Cobimetinib) https://www.exelixis.com/our-science/cotellyc-obimetinib